Fig. 7.

(A) DB16, DB21, and 6DBF7 were tested in the LS174T lung cancer mouse model. As with the B16F10 model, tumors were allowed to grow to approximately 50 mm³. Treatment was initiated on day 8 by i.p. injection twice daily for a total dose of 10 mg/kg/day for 7 days. A control group of animals was treated with PBS alone. (B) As a preliminary assessment of pharmacodynamics in mice, we used the slower-growing MA148 tumor model, in which tumors grew to about 70 mm³ in 35 days. Treatment was then initiated with DB21 in four groups of animals (n = 10 each): control; two injections on days 35 and 42; three injections on days 35, 40, and 45; and five injections on day 35, 38, 41, 44, and 47. Tumor volumes in (A) and (B) are plotted as cubic millimeters versus days postinoculation (for all groups n = 11, ±S.E.M.). Tumor volumes were determined by measuring diameters of tumors using calipers, and the equation for the volume of a spheroid, (a² × b × Π) / 6, where “a” is the width and “b” the length of the tumor. Tumor weights correlated well with tumor volumes calculated in this way.